Table 1.

Baseline demographic and clinical characteristics in patients with adult-onset idiopathic inflammatory myopathies.

CharacteristicsTotal, n = 197ADM, n = 21DM, n = 74PM, n = 43OM, n = 38CAM, n = 21Comparison in All Groups (DM vs PM)
Mean age at initial visit (SD)54 (14)58 (16)54 (13)53 (16)53 (14)61 (12)NS (NS)
Women, %707668638462NS (NS)
Raynaud’s phenomenon, %19141916355NS (NS)
Arthritis, %424341356324NS (NS)
Typical rash, %6110010001890Yesa (p < 0.0001)
Skin ulcers, %557080NS (NS)
Dysphagia, %21020102265Yesb (NS)
Manual muscle testing (IQR)82 (72–88)90 (90–90)80 (70–88)82 (72–87)79 (72–88)75 (65–82)Yesc (NS)
Interstitial lung disease, %647173497633Yesd (p = 0.0102)
Myocarditis, %17101428270NS (p = 0.0842)
Creatine kinase (IQR)923 (280–2582)111 (71–187)664 (221–2014)1733 (822–3797)1366 (766–3064)1214 (419–3991)Yese (p = 0.0008)
Antinuclear antibodies, %454332476360Yesf (NS)
Anti-Jo-1 antibodies, %16014242115NS (NS)
Median followup for survivors, mo (IQR)57 (26–114)44 (20–98)54 (24–122)65 (24–112)62 (46–109)60 (14–116)NS (NS)
Median followup for fatalities, mo (IQR)7, n = 53 (2–34)1, n = 7 (1–30)3, n = 20 (1–22)39, n = 5 (4–111)46, n = 7 (5–65)17, n = 14 (4–26)NS (p = 0.1104)
  • a ADM vs PM and OM, DM vs PM and OM, PM vs OM and CAM, OM vs CAM, p < 0.05.

  • b CAM vs ADM, DM, PM, and OM, p < 0.05.

  • c ADM vs CAM, OM, DM, and PM, p < 0.05.

  • d CAM vs DM and OM, p < 0.05.

  • e ADM vs DM, PM, OM, and CAM, DM vs PM, p < 0.05.

  • f DM vs OM, p < 0.05. ADM: amyopathic dermatomyositis; DM: dermatomyositis; PM: polymyositis; OM: overlap myositis; CAM: cancer-associated myositis; IQR: interquartile range; NS: not significant.